Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2Phase 1 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Melanoma 4Skin Neoplasms 2Neoplasm Metastasis 2Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Kidney Neoplasms 1Eyelid Squamous Cell Carcinoma 1Cutaneous Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Merkel Cell 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Anus Neoplasms 1Adenocarcinoma 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × cemiplimab × Clear all
NCT03257267 2025-04-08

Study of Cemiplimab in Adults With Cervical Cancer

Regeneron Pharmaceuticals

Phase 3 Completed
608 enrolled 18 charts

Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡